Jimmi Nielsen1, Rasmus Røge2, Sofie Gry Pristed3, Anne Grethe Viuff4, Henrik Ullum5, Lise Wegner Thørner5, Thomas Werge6, Torkel Vang7. 1. jin@rn.dk. 2. Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark; 3. Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark; 4. Regional Psychiatric Services West, Herning, Denmark; 5. Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 6. Institute of Biological Psychiatry, Copenhagen Mental Health Services; Department of Clinical Medicine, University of Copenhagen; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen, Denmark. 7. Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark; Psychiatry in Vestfold, Tønsberg, Norway;
Abstract
BACKGROUND: The etiology of schizophrenia remains largely unknown but alterations in the immune system may be involved. In addition to the psychiatric symptoms, schizophrenia is also associated with up to 20 years reduction in life span. Soluble urokinase-type plasminogen activator receptor (suPAR) is a protein that can be measured in blood samples and reflects the levels of inflammatory activity. It has been associated with mortality and the development of type 2 diabetes and cardiovascular disease. METHODS: suPAR levels in patients with schizophrenia were compared to healthy controls from the Danish Blood Donor Study. SuPAR levels were dichotomized at >4.0 ng/ml, which is considered the threshold for low grade inflammation. A multiple logistic regression model was used and adjusted for age, sex, and current smoking. RESULTS: In total we included 1009 subjects, 105 cases with schizophrenia (10.4%) and 904 controls (89.6%). The mean suPAR values were 4.01 ng/ml (SD = 1.43) for the cases vs 1.91 ng/ml (SD = 1.35) for the controls (P < .001). Multiple logistic regression with odds ratio (OR) for suPAR levels >4.0 ng/ml yielded: schizophrenia, OR: 46.15 95% CI 22.69-93.87, P < .001; age, OR: 1.02 95% CI 0.99-1.02, P = .15; male sex, OR: 0.70 95% CI 0.35-1.36, P = .29; and current smoking, OR: 3.51 95% CI 1.78-6.94, P < .001. CONCLUSIONS: Patients with schizophrenia had significantly higher suPAR levels than healthy controls. Further studies are warranted to clarify if elevated suPAR levels are involved in the pathophysiology of schizophrenia and/or the increased mortality found in patients with schizophrenia.
BACKGROUND: The etiology of schizophrenia remains largely unknown but alterations in the immune system may be involved. In addition to the psychiatric symptoms, schizophrenia is also associated with up to 20 years reduction in life span. Soluble urokinase-type plasminogen activator receptor (suPAR) is a protein that can be measured in blood samples and reflects the levels of inflammatory activity. It has been associated with mortality and the development of type 2 diabetes and cardiovascular disease. METHODS:suPAR levels in patients with schizophrenia were compared to healthy controls from the Danish Blood Donor Study. SuPAR levels were dichotomized at >4.0 ng/ml, which is considered the threshold for low grade inflammation. A multiple logistic regression model was used and adjusted for age, sex, and current smoking. RESULTS: In total we included 1009 subjects, 105 cases with schizophrenia (10.4%) and 904 controls (89.6%). The mean suPAR values were 4.01 ng/ml (SD = 1.43) for the cases vs 1.91 ng/ml (SD = 1.35) for the controls (P < .001). Multiple logistic regression with odds ratio (OR) for suPAR levels >4.0 ng/ml yielded: schizophrenia, OR: 46.15 95% CI 22.69-93.87, P < .001; age, OR: 1.02 95% CI 0.99-1.02, P = .15; male sex, OR: 0.70 95% CI 0.35-1.36, P = .29; and current smoking, OR: 3.51 95% CI 1.78-6.94, P < .001. CONCLUSIONS:Patients with schizophrenia had significantly higher suPAR levels than healthy controls. Further studies are warranted to clarify if elevated suPAR levels are involved in the pathophysiology of schizophrenia and/or the increased mortality found in patients with schizophrenia.
Authors: Gustaf Edgren; Trung Nam Tran; Henrik Hjalgrim; Klaus Rostgaard; Agneta Shanwell; Kjell Titlestad; Agneta Wikman; Rut Norda; Casper Jersild; Louise Wideroff; Gloria Gridley; Johanna Adami; Mads Melbye; Olof Nyrén; Marie Reilly Journal: Transfusion Date: 2007-11 Impact factor: 3.157
Authors: Anita W Rijneveld; Marcel Levi; Sandrine Florquin; Peter Speelman; Peter Carmeliet; Tom van Der Poll Journal: J Immunol Date: 2002-04-01 Impact factor: 5.422
Authors: Sisse R Ostrowski; Henrik Ullum; Bamenla Q Goka; Gunilla Høyer-Hansen; George Obeng-Adjei; Bente K Pedersen; Bartholomew D Akanmori; Jørgen A L Kurtzhals Journal: J Infect Dis Date: 2005-03-14 Impact factor: 5.226
Authors: Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton Journal: Mol Neuropsychiatry Date: 2015-07-08
Authors: Thomas Folkmann Hansen; Karina Banasik; Christian Erikstrup; Ole Birger Pedersen; David Westergaard; Piotr Jaroslaw Chmura; Kaspar Nielsen; Lise Thørner; Henrik Hjalgrim; Helene Paarup; Margit Anita Hørup Larsen; Mikkel Petersen; Poul Jennum; Steffen Andersen; Mette Nyegaard; Gregor Borut Ernst Jemec; Jes Olesen; Thomas Werge; Pär I Johansson; Erik Sørensen; Søren Brunak; Henrik Ullum; Kristoffer Sølvsten Burgdorf Journal: BMJ Open Date: 2019-06-09 Impact factor: 2.692